We are pleased to announce that we have submitted an EU-Horizon 2020 proposal for a new trial and project to complement GLORIA.
In Call PM10, the EU requested proposals for studies "evaluating existing health care in the adult population”. The call text was almost identical to the call text on the elderly in which GLORIA was successful.
As more than half of the RA population is not elderly, we felt this call would be a great opportunity to extend the trial question to non-elderly patients (65-). In Excelsis will have the same design as GLORIA, but add e-and m-health innovation initiatives, to explore alternative ways of data capture and feedback. Combining data from both trials will provide health professionals and patients with "iron-clad" data on the balance of benefit and harm of low dose glucocorticoids in the treatment of rheumatoid arthritis.
The proposal is now submitted for the first stage, we hope to get the green light to fully develop the proposal for the second stage in January 2017.